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Introduction
The long chain polyunsaturated fatty acids (LCPUFA) docosahexaenoic acid (DHA, C22: 6 ω-3) and eicosapentaenoic acid (EPA, C20: 5ω-3) have been shown to possess immunomodulatory properties and are abundant in oily fish (1, 2) . Observational studies report that oily fish in the maternal diet during pregnancy (3) as well as in the infant's diet during the first year (4) decreases the risk of allergic sensitisation and disease later in life.
Furthermore, although still controversial, low levels of DHA and EPA have been demonstrated both in cord blood of infants who later develop allergies, and in children with allergic disease (5) . Immune responses against antigens have been detected in the fetus as early as at the 25th gestational week (gw) (6) , and possible protective effects from dietary supplementation with EPA and DHA during pregnancy have been reported on sensitisation and severity of eczema in infants (7) as well as on asthma in adolescents (8) . We previously reported a protective effect of maternal DHA and EPA supplementation in pregnancy and lactation on skin sensitisation, IgE mediated food reactions and IgE associated eczema during the first year of life (9) . Thus, the primary aim of this report is to corroborate these findings at 24 months of age in the infants and to assess whether there is a relationship between the proportions of DHA, EPA and the AA (arachidonic acid, C 20:4ω-6)/EPA ratios in maternal and infant plasma phospholipids and the frequency of IgE associated disease. The first year we found no effect on the prevalence of clinical symptoms per se (9) and the immediate clinical significance of the low rate of early IgE associated disease was not elucidated even though it might be beneficial for lowering the asthma prevalence later in life (10) . In this report the severity of eczema and number of allergic symptoms up to two years of age in the infants are related to maternal ω-3 supplementation and maternal and infant DHA, EPA and AA/EPA ratios in plasma phospholipids.
Material and Methods

Inclusion and dietary intervention
In summary, 145 pregnant women were recruited through antenatal care clinics during a twoyear period in [2003] [2004] [2005] . At least one family member had current or previous allergic symptoms i.e. bronchial asthma, eczema, allergic food reactions, itching and running eyes and nose at exposure to pollen, pets or other known allergens. The clinical symptoms were assessed in a structured interview performed by one of the three research nurses (9) .
Exclusion criteria were allergy to soy or fish, treatment with anti-coagulants or ω-3 fatty acid supplements. The mothers were randomised to dietary supplementation with nine capsules a day containing ω-3 fatty acids (35% EPA, 1.6 g/day and 25% DHA, 1.1 g/day, n=70) or soybean oil (58% linoleic acid, LA, 2.5 g/day and 6% -linolenic acid, LNA, 0.28 g/day, n=75) as a placebo through numbered containers prepared by the producer (Pharma Nord, Vejle, Denmark). The mothers, as well as the staff handling clinical and laboratory follow up, were blinded to group allocation and the mothers were identified by their study number only.
In both preparations the antioxidant -tocopherol was used in similar amounts (ω-3 group: 28 mg/day placebo: 36 mg/day) to assure the stability of the oil. The supplementation started at the 25th week of gestation and the mean time of supplementation was 30.7 weeks (SD: +/-5.8 w range: 15.1 -42.1, -3: 29.8 weeks, placebo: 31.3 weeks, ns). Sixteen (23%) of the mothers in the -3 LCPUFA and nine (12%) in the placebo group did not complete the minimum 15 weeks of supplementation required, i.e. throughout pregnancy. On average, these mothers took the supplementation for 5.3 weeks (SD 3.4) in the ω-3 supplemented group and 5.3 weeks (SD 4.2) in the placebo group. Reasons for discontinuing the intervention were inability to swallow capsules (n=9), nausea (n=6), abdominal pain (n=3), forgot to take capsules (n=3) and miscellaneous (n=4). The content of the capsules did not have an impact on reasons for withdrawal.
Follow up and data collection
The families were followed up according to Figure I . Research nurses assessed the infants at 3, 6 and 12 months of age. A paediatrician (JL or CF) examined the infants at any time if clinical symptoms of allergic disease were suspected and all infants were examined at 24 months of age. The severity of eczema was assessed by rating according to SCORAD (11) .
Blood samples were taken from the mothers one week after delivery and from the infants at delivery (cord blood) and at 3, 12 and 24 months of age. The samples were immediately frozen and stored at -70 C. The families completed validated allergy questionnaires (12) regarding environmental factors, the infant's diet and development of clinical symptoms in the infant at 3, 6, 12 and 24 months of age. The -3 group and the placebo group were similar regarding possible confounders; maternal allergic symptoms, maternal positive Phadiatop®, eczema or food reactions in the immediate family, breastfeeding at 3 and 6 months, number of siblings (9), day care attendance, one or two parents with allergic disease and exposure to tobacco smoke or furry pets up to two years of age (data not shown) but caesarean sections were more common in the placebo group (14/66, 21% compared to the ω-group (4/54, 7%, p<0.05). Ninety-seven percent of the mothers in the intervention groups breast fed, at least partly, at three months and 87% at 6 months. No formula containing long chain ω-3 fatty acids was used. After 4 weeks of supplementation some mothers reported belching; 11/80 (14%) and 10/11 were supplemented with -3 fatty acids (p=0.001). At the follow-up investigations, the staff was instructed not to ask any specific questions that could reveal maternal opinion regarding group allocation. The mothers who were unable to complete the intervention (n=25) were invited to a clinical examination of their infants comprising skin prick tests (SPTs) but no blood sampling at 6 and 24 months (Fig.1) . Thus, a follow up at 2 years was accomplished for 143/145 families.
A certified dietician assessed the maternal dietary intake of energy, total fat and -6 and -3 polyunsaturated fatty acids from maternal food diaries filled out three days in a row at 25 th gestational week and 6 months after delivery. The results were the same in the -3 and placebo groups (9) . These finding were reflected in similar proportions of DHA and EPA in maternal plasma phospholipids in both groups before supplementation (9) . None of the mothers or infants took any additional fatty acid supplements.
Clinical definitions
Food reaction: gastrointestinal symptoms, hives, aggravated eczema or wheezing following ingestion of a certain food with recovery after food elimination and reoccurrence of symptoms after reingestion of the particular food. If food specific positive SPT or serum IgE antibodies were present, the food reaction was considered as IgE mediated. Eczema: reoccurring and itching eczematous, lichenified or nummular dermatitis, according to the definition by Seymour in 1987 (13) . If detectable IgE antibodies or a positive SPT were present, it was defined as IgE associated eczema. Asthma: doctor diagnosed wheezing at least three times during the first two years (14) . IgE associated asthma was defined as asthma with the presence of IgE antibodies or positive SPT. Rhinoconjunctivitis: seasonal itching and running eyes and nose. It was considered as IgE mediated if there was corresponding positive SPT or detectable specific IgE antibodies. Symptoms of eczema, food reaction, asthma or rhinoconjunctivitis were considered as clinical symptoms of allergic disease. Concomitant sensitisation defined IgE associated allergic disease.
Sensitization
Maternal serum IgE antibodies to a panel of inhalant antigens (Phadiatop®) were analysed by the UniCap® Pharmacia CAP System™ (Phadia, Uppsala, Sweden).
SPTs were performed in the infants at 6 and 12 months of age with milk, egg, wheat and cat.
At 24 months of age, timothy and birch were added to the test panel. Food allergens were tested prick to prick and the inhalant allergens were extracts purchased from ALK-ABELLÓ, Hørsholm, Denmark, Soluprick®. A wheal diameter ≥ 3 mm was considered positive. Specific IgE antibodies towards egg, milk, wheat and cat were analyzed in serum samples from the infants at 12 and 24 months of age. At 24 months timothy-grass and birch were added to the analysis. The detection limit was 0.35 kU/l.
Fatty acid analysis
Analysis of phospholipids was performed separating lipid fractions on a SEP-PAK aminopropyl cartridge (Waters Sverige AB, Sollentuna, Sweden) according to a method originally described by Kaluzny et al.(15) . Samples were trans-methylated in methanolicHCl-3N (VWR) at 80° C for 4 h. The fatty acid methyl esters were separated by Agilent Technologies 6890N Network GC System gas chromatograph (Agilent Technologies, Stockholm, Sweden). C21:0 methyl ester (Larodan, Malmö, Sweden) was added as an internal standard and the fatty acid methyl esters were identified by comparing the retention times of the peaks with those of a known standard (Mixture Me 100, Larodan Fine Chemicals AB, Malmö, Sweden). The levels were expressed as mol% (16) .
Statistics
Power calculations for planning adequate sample size were performed based on a previous study (17) . In order to detect a 40% difference in the prevalence of clinical symptoms of allergic disease, with 80% power and a probability of 0.05 at least 134 women had to be included in this study. The categorical data of the two groups were analyzed by chi-2 tests and when the expected count was less than 5, the Fisher's exact test was used. The means of the continual variables by Student's t-test. If not normally distributed, the Mann-Whitney test was applied. Multiple logistic regression was used to calculate the odds ratios for developing allergic sensitisation and disease in the ω-3 supplemented group compared to the placebo group and to find confounders in the comparison between subgroups (Fig 2, Table 4 ). Maternal AA levels at inclusion were not equal in the two groups in spite of randomization and were therefore considered as possible confounders in addition to the factors described in the Follow up and data collection. All confounders were run in the model and effect modifiers (altering the odds ratio >10%), identified for each outcome, were considered in calculating adjusted odds ratios (aOR). Mother-infant pairs were divided into groups according to quartile of phospholipid -3 proportions (Fig 2) and were related to the frequency of infant IgE associated disease. Chi-2 and Chi-2 trend (Extended Mantel-Haenszel chi-square test for linear trend) were used to assess the differences in prevalence of IgE associated disease between the quartile groups. A difference was considered statistically significant at a two-tailed p-value of < 0.05. Statistic analyses were performed using SPSS software 15.0 for Windows (SPSS Inc, Chicago, Illinois, USA).
Ethical considerations
The Human Research Ethics Committee of the Medical Faculty at Linköping University approved the study. All parents gave written informed consent.
Results
Sensitization and allergic symptoms
The cumulative incidence (0-24 m) of positive SPTs, particularly to food, in the -3 group was lower compared to the placebo group but symptoms of allergic disease in the infants were equally frequent in the two groups (Table 1) . IgE mediated food reactions, IgE associated eczema and any IgE associated disease were, however, significantly less frequent in the -3 group compared to the placebo group during the infant's first two years of life (Table 1) .
Crude and adjusted odds ratios are presented in Table 2 . When analysing the subgroup of children whose mothers did not have allergic symptoms separately there was still a trend towards lower incidence of IgE associated disease in the ω-3 group (ω-3: 1/14, 7% vs. placebo: 9/23, 39%, p= 0.056) while it was not as evident in the group of children with maternal history of allergy (ω-3: 5/40, 13% vs. placebo: 10/39, 26%, p = 0.14). There were no significant differences between the -3 group and the placebo group regarding the point prevalence of sensitisation or allergic symptoms or IgE associated disease at 24 months of age (Table 1) .
Among the 25 mothers who did not complete the intervention (Fig.1 ) 15/24 (62%) reported allergic symptoms in the infant and 7/18 infants (38 %) were diagnosed with IgE associated disease up to 24 months. These results did not differ from the placebo group but were significantly higher than in the -3 group (p = 0.03 and 0.01 respectively).
In an intention to treat analysis there was a trend towards a lower cumulative incidence of positive SPT´s to food and IgE associated disease in the ω-3 supplemented group compared to the placebo group (p=0.06-0.07, data not shown).
Plasma proportions of LCPUFA.
Mothers and infants in the ω-3 supplemented group had higher plasma proportions of ω-3 LCPUFA compared to the placebo group during the first year but this difference was not apparent in the infants at two years of age (Table 3) .
We divided the mother-infant pairs into quartiles according to maternal phospholipid proportions of DHA and the AA/EPA ratios (Fig 2) , in parallel with the report by Mihrshahi et al (18) . For each quartile the frequency of IgE associated disease, allergic symptoms without sensitisation, and absence of allergic symptoms with or without sensitisation in the infants are given in Fig 2. The cumulative incidence of IgE associated disease was lower in the groups of children whose mothers were in the higher quartiles of phospholipid DHA (Fig   2A) and also among the infants with DHA proportions in the higher quartiles at 12 months of age (Chi-2: p = 0.05, p for trend = 0.003, data not shown). No such relations were found for exposure quartiles of infant DHA proportions in cord blood phospholipids at 3 or 24 months of age. The opposite results were found regarding the AA/EPA ratio, i.e. mothers with AA/EPA ratios in the lower quartiles less often gave birth to children with IgE associated disease (Fig.2B ). There was also significant trends towards lower incidence of IgE associated disease in the lower quartiles of AA/EPA ratios in infant phospholipids at birth and at 3 months of age (Chi-2: p = ns for both, but p for trend = 0.01 and 0.03 respectively, data not shown) but not in infant phospholipids at 12 nor at 24 months (data not shown). In a multiple regression model no confounders were found that significantly changed these results. We found no associations between LA or LNA proportions in mother or infant at any time point and allergic disease, sensitisation or IgE associated disease (data not shown).
Severity of allergic disease.
Regardless of sensitisation, 32% (6/19) of the infants with clinical allergic symptoms in the ω-3 group and 50% (14/28) in the placebo group had more than one allergic symptom, i.e. eczema, food allergy, asthma and/or rhinoconjunctivitis during the first two years of life (ns).
However, the proportions of DHA and EPA were higher and the AA/EPA ratios were lower in maternal and infant phospholipids if the infant was non-symptomatic, compared to the infants who developed two or more allergic symptoms (p< 0.05 at several time points, Table   4 ). Furthermore, in all infants, more than one allergic symptom during the first two years of life was more frequent in infants with IgE associated disease than in the group of symptomatic infants without sensitisation (16/24, 67% compared to 3/20, 15%, p = 0.001).
Mean SCORAD among the infants with eczema in the placebo group was 13.3 (SD 7.2, n = 20) and in the ω-3 group 17.8 (SD 9.6, n = 11, ns). The infants were evaluated in average 2.6 times in both groups during the follow up with the highest score included in the analysis but merely two infants had SCORAD > 25. There was no association between SCORAD rates and fatty acid status (data not shown).
Discussion
In this study, we report that maternal supplementation with -3 PUFA during pregnancy and lactation is related to lower cumulative incidence of allergic sensitisation and IgE related disease up to 24 months of age. We further report a significant relationship between higher-3 PUFA proportions in maternal and infant phospholipids and lower frequency and less severity of allergic disease during the first two years of life.
Our findings corroborate in some aspects previous reports. Two earlier trials have evaluated -3 supplementation during pregnancy in relation to sensitisation (7) and asthma (8) in the infants. In the study by Dunstan et al (7) it was shown that daily dietary supplementation with 1.1 g EPA and 2.2 g DHA to atopic mothers during late pregnancy (n=89) lowered the risk of sensitisation to egg and severe eczema (SCORAD > 25) at 12 months in the ω-3 as compared to the placebo supplemented group the first year of life, but the infants were not examined at 24 months or later for allergic outcomes (7) . A population-based study by Olsen et al found a lower prevalence of allergic asthma in teenagers whose mothers had received 2.7 g -3
LCPUFA during the second half of pregnancy (n=263) as compared to adolescents whose mothers had received olive oil (n=136). However, this difference did not appear when comparing the fish oil group to a group whose mothers received no supplement (8) . In our study, the prevalence of allergic symptoms and IgE associated disease in the group whose mothers did not complete the intervention was similar to the placebo group and significantly higher than in the -3 supplemented group, strengthening our results.
In the CAPS study mothers (n =376) were supplied with low ω-6 PUFA containing oils and margarines from 36 weeks of gestation. After weaning the infants received 500 mg tuna fish oil daily (37% ω-3 PUFA; 185 mg daily). At 18 months of age there was a decreased prevalence of wheeze in the fish oil group and higher plasma ω−3 PUFA levels were associated with lower bronchodilator use, irrespective of the supplementation group (18) . The infants were given a rather low dose of ω-3 and DHA and EPA were not analysed separately in relation to IgE associated manifestations, which could explain the lack of dose response relationship. Follow-up at 3 years indicated that the fish oil group had reduced cough, but not wheeze (19) . However, no effect of fish oil supplementation was seen on the other endpoints measured such as eczema, serum IgE concentration, or doctor's diagnosis of asthma.
Our sample size was calculated based on the cumulative incidence of allergic disease during the first 18 months of life (17) . However, for instance the cumulative incidence of eczema in this study was 20% in the -3 and 31 % in the placebo group, and thus less common than expected. In order to dismiss such a difference between the two groups as a type II error, with an 80% power at a 0.05 significance level, 246 mothers would have been needed in each group. Nevertheless, we found significantly lower frequencies of IgE associated disease in the infants during this period. Thus, the relationship between-3 supplementation and clinical symptoms combined with allergic sensitisation seem to be of more biological importance than clinical symptoms alone. The objective of this study was not to evaluate the tolerability or the dose of fish oil; it was mainly to prove any effect at all from fish oil supplementation.
However, when performing an intention to treat analysis the preventive effect of the supplementation was not obvious, suggesting that increased compliance would be preferable, maybe by decreasing the daily dose to make it more tolerable.
The low prevalence of allergic symptoms and sensitisation in the infants at 24 months of age in this study reflects the general decrease of these symptoms commonly seen after the first year (20, 21) . To rule out any effect from the -3 supplementation on the point prevalence of allergic symptoms or sensitisation at 24 months, 300 infants/group are needed, which is a study beyond our ability.
When pooling patients regardless of the supplementation, we found an inverse dose response association between high ω-3 fatty acids in mother and infants and appearance of IgE associated disease during the first two years of life. This thus suggests that the higher the levels of ω-3 LCPUFA in serum, the lower the risk of developing IgE associated disease in the infants during the first 2 years of life. However, this does not tell us the maternal dose required in order to protect her infant from IgE associated disease. We also observed an association between high DHA and EPA proportions and low AA/EPA ratios in maternal and infant plasma phospholipids and a less severe disease, expressed as number of symptoms.
Presumably, this might be associated to the decrease in allergic sensitisation among the infants presenting clinical symptoms. The relationship between disease severity and allergic sensitisation found in this study strengthens this explanation. Hence, -3 PUFA supplementation, although not preventing the development of clinical disease, may represent a significant clinical benefit for the families by preventing allergic sensitisation. Animal studies, reporting that dietary DHA and EPA may resolve inflammation and hamper the severity of the allergic disease, corroborate these findings (22) .
Our SCORAD data was not associated to the supplementation or phospolipid fatty acids but the significance of the SCORAD may be questioned. The ratings were generally very low due to close follow up and intense treatment of infants from families with previous experience of eczema.
As expected in this age group, asthma, and particularly IgE associated asthma, was rare in our study. However, early development of eczema and skin sensitisation to food, particularly egg, in the first two years of life, is related to an increased risk of later development of asthma bronchiale (10) which highly motivates further follow up regarding asthma and sensitisation against inhalant allergens among the infants in this study.
DHA and EPA may act through several anti-inflammatory mechanisms. They inhibit expression of inflammatory genes (COX-2, IL-1α, 5-LOX etc) and adhesion molecules, influence the antigen presenting cells (23) , reduce lymphocyte proliferation (24) and alter cytokine production (25) . Low AA/EPA ratios in maternal plasma were associated with low incidence of IgE associated disease in the infants in this study. EPA and AA compete for the In this study maternal blinding might be incomplete due to fish tasting belching reported by some mothers in the -3 supplemented group and diagnosis of clinical symptoms is dependent on the mother's description and expectations. However, positive SPTs and detection of specific IgE antibodies in blood samples are objective measures. Further, all staff members working with the intervention and follow up were blinded throughout the whole study.
The rationale for soybean oil as a reliable placebo in this study may be questioned. Despite the LA content in the placebo capsule (2.5 g/d, in relation to daily dietary intake of 8.0 g/d LA in the placebo and 7,7 g/d in the -3 supplemented mothers) the maternal and infant LA and AA plasma proportions in the placebo group corresponded to previous observations in normal pregnancy (26) and early infancy (27) . The proportions of LA and AA in the ω-3 group decreased compared to the placebo group due to the increase of ω-3 proportions as previously shown (28) . Furthermore, LA levels were not associated to allergic disease or sensitisation in the infant at any point. However, the content of vitamin E in the oils differed somewhat between the two groups. Vitamin E is an antioxidant with a recommended daily intake during pregnancy of 15-20 mg. It has been reported to possibly decrease the risk of developing asthma, eczema (29) and sensitization (30) in childhood. However, the reduced risk of sensitisation has been seen at intakes of vitamin E below up to but not above 7 mg/day (30) and all mothers in this study received more than 25 mg/day.
In conclusion ω-3 PUFA supplementation decreases the cumulative incidence of IgE associated disease up to 2 years of life and this effect was related to maternal and infant ω-3 LCPUFA plasma proportions in a dose dependent manner. The ω-3 LCPUFA might mitigate the severity of the allergic phenotype, possibly through preventing allergic sensitisation, as high maternal and infant plasma ω-3 proportions were associated with fewer allergic symptoms in the infants.
This suggests that fish oil in the diet during pregnancy and early in life may be important if there is a high risk for allergies in the family. The value of decreasing allergic sensitisation in early life by ω-3 PUFA supplementation for the development of asthma bronchiale later in life needs to be further assessed. months, ¶ =Food reaction and sensitisation to the particular food (egg or milk), ** =Eczema and sensitisation, † † = Two children with eczema and negative SPT´s were excluded from the analysis due to missing IgE data, ‡ ‡ =Asthma and sensitisation, # = one child with asthma and negative SPT´s, was excluded from the analysis due to missing IgE data, ¤ =Rhinoconjunctivits and sensitisation, £ =cat, birch and/or timothy. The total n values in each group vary due to missing IgE and SPT data caused by technical difficulties. Table 2 . The risk (odds ratio = OR) of developing positive skin prick tests against foods and symptoms of allergic disease in children of mothers supplemented with ω-3 PUFA or placebo during pregnancy and lactation. All the data is presented as cumulative incidence for the first 24 months of life of the children. The OR were adjusted for effect modifiers identified in the multiple regression model. c=clinical diagnosis of eczema and positive SPT/IgE to egg, milk and/or wheat. d = eczema, food reaction, asthma and / or rhinoconjunctivitis AND sensitisation. e = OR adjusted for AA (arachidonic acid) levels in maternal phospholipids at inclusion and breastfeeding fully until 6 months. f = OR adjusted for AA levels in maternal phospholipids at inclusion and allergic symptoms in mother. g = OR adjusted for AA levels in maternal phospholipids at inclusion, eczema in the family and caesarean section. Table 4 . DHA (C22: 6n-3), and EPA (C20: 5n-3) proportions and AA (C18: 2n-6)/EPA (C20: 5n-3) ratios in maternal and infant plasma phospholipids related to number of allergic symptoms, with or without sensitisation, in the children up to two years of age. Information is given on all mothers/infants with available samples, regardless of maternal group allocation. 
